These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9399547)

  • 1. Susceptibilities of Chryseobacterium indologenes and Chryseobacterium meningosepticum to cefepime and cefpirome.
    Hsueh PR; Teng LJ; Yang PC; Ho SW; Luh KT
    J Clin Microbiol; 1997 Dec; 35(12):3323-4. PubMed ID: 9399547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of cefepime and cefpirome compared to other third-generation cephem antibiotics against gram-negative nosocomial pathogens.
    Tumah HN
    Pharmazie; 2004 Nov; 59(11):854-8. PubMed ID: 15587586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative antimicrobial activity of FK037, cefpirome, ceftazidime and cefepime against aminoglycoside-sensitive and aminoglycoside-resistant Pseudomonas aeruginosa and Pseudomonas spp.
    Baltch AL; Smith RP; Ritz W
    Chemotherapy; 1994; 40(6):391-8. PubMed ID: 7842822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility of Klebsiella spp. to cefpirome and cefepime.
    Tuchiluş C; Poiată A; Iancu LS; Bădicuţ I; Ambăruş A; Buiuc D
    Rev Med Chir Soc Med Nat Iasi; 2006; 110(2):465-7. PubMed ID: 17802963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial susceptibility of flavobacteria as determined by agar dilution and disk diffusion methods.
    Chang JC; Hsueh PR; Wu JJ; Ho SW; Hsieh WC; Luh KT
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1301-6. PubMed ID: 9174188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bactericidal activity of cefpirome (HR 810) against 513 gram-negative bacteria isolated from blood of septicemic patients.
    Bergeron MG; Bernier M
    Infection; 1994; 22(4):299-305. PubMed ID: 8002094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increasing incidence of nosocomial Chryseobacterium indologenes infections in Taiwan.
    Hsueh PR; Teng LJ; Yang PC; Ho SW; Hsieh WC; Luh KT
    Eur J Clin Microbiol Infect Dis; 1997 Aug; 16(8):568-74. PubMed ID: 9323467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicentre comparative study on the antibacterial activity of FK-037, a new parenteral cephalosporin.
    Martínez-Beltrán J; Cantón R; Liñares J; García de Lomas J; Gimeno C; Tubau F; Baquero F
    Eur J Clin Microbiol Infect Dis; 1995 Mar; 14(3):244-52. PubMed ID: 7614970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology units. Belgian Multicentre Study Group.
    Piérard D; Emmerechts K; Lauwers S
    J Antimicrob Chemother; 1998 Apr; 41(4):443-50. PubMed ID: 9598775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of inoculum size on the antibacterial activity of cefpirome and cefepime against Klebsiella pneumoniae strains producing SHV extended-spectrum beta-lactamases.
    Bedenić B; Beader N; Zagar Z
    Clin Microbiol Infect; 2001 Nov; 7(11):626-35. PubMed ID: 11737087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
    Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chryseobacterium (Flavobacterium) meningosepticum outbreak associated with colonization of water taps in a neonatal intensive care unit.
    Hoque SN; Graham J; Kaufmann ME; Tabaqchali S
    J Hosp Infect; 2001 Mar; 47(3):188-92. PubMed ID: 11247678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in vitro activity of cefepime (BMY 28142) against multiresistant nosocomial isolates of Pseudomonas aeruginosa.
    Voutsinas D; Mavroudis T; Avlamis A; Giamarellou H
    Eur J Clin Microbiol Infect Dis; 1989 Oct; 8(10):917-9. PubMed ID: 2512141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity and stability against novel beta-lactamases of investigational beta-lactams (cefepime, cefpirome, flomoxef, SCE2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin).
    Bauernfeind A; Schweighart S; Eberlein E; Jungwirth R
    Infection; 1991; 19 Suppl 5():S264-75. PubMed ID: 1664418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vitro activity of FK 037 (Cefoselis), a novel 4(th) generation cephalosporin, compared to cefepime and cefpirome on nosocomial staphylococci and gram-negative isolates.
    Giamarellos-Bourboulis EJ; Grecka P; Tsitsika A; Tympanidou C; Giamarellou H
    Diagn Microbiol Infect Dis; 2000 Mar; 36(3):185-91. PubMed ID: 10729661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activities of cefepime alone and with amikacin against aminoglycoside-resistant gram-negative bacteria.
    Fung-Tomc J; Huczko E; Kolek B; Thater C; Kessler RE
    Antimicrob Agents Chemother; 1991 Dec; 35(12):2652-4. PubMed ID: 1810203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reappraisal of the antimicrobial susceptibilities of Chryseobacterium and Flavobacterium species and methods for reliable susceptibility testing.
    Fraser SL; Jorgensen JH
    Antimicrob Agents Chemother; 1997 Dec; 41(12):2738-41. PubMed ID: 9420049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chryseobacterium meningosepticum: an emerging pathogen among immunocompromised adults. Report of 6 cases and literature review.
    Bloch KC; Nadarajah R; Jacobs R
    Medicine (Baltimore); 1997 Jan; 76(1):30-41. PubMed ID: 9064486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in-vitro activities of newer cephalosporins cefclidin, cefepime, and cefpirome against ceftazidime- or imipenem-resistant Pseudomonas aeruginosa.
    Watanabe N; Hiruma R; Katsu K
    J Antimicrob Chemother; 1992 Nov; 30(5):633-41. PubMed ID: 1493980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.